Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0VRQ vs LGND, DFTX, XENE: Debt-to-Asset Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Debt-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Debt-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (LTS:0VRQ) has a Debt-to-Asset of 0.30 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Debt-to-Asset too high?
CRISPR Therapeutics AG's current Debt-to-Asset is 0.30. Overall, CRISPR Therapeutics AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Debt-to-Asset compare to LGND and DFTX?
CRISPR Therapeutics AG's Debt-to-Asset of 0.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Debt-to-Asset is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.68, compared to a current price of $58.33 — trading 926.9% above its estimated fair value. The current Debt-to-Asset is 0.30. CRISPR Therapeutics AG's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Debt-to-Asset is 0.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $58.33 is trading 926.9% above its estimated GF Value™ of $5.68.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for LTS:0VRQ:
Debt-to-Asset: 0.30
GF Value™: $5.68 vs. price of $58.33 (926.9% above fair value)
No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CRISPR Therapeutics AG is a Swiss biopharmaceutical company focused on developing gene-editing medicines based on CRISPR/Cas9 technology, which enables precise modification of genomic DNA. Its lead product, Casgevy, was developed with Vertex Pharmaceuticals and is approved for sickle cell disease and transfusion-dependent beta-thalassemia. The company also advances programs in immuno-oncology, cardiovascular disease, and a stem-cell-derived therapy for type 1 diabetes, alongside in vivo editing approaches. CRISPR Therapeutics conducts research and development across sites in Switzerland, the United States, and Canada, and generates revenue through collaboration and licensing agreements, including with Vertex, as well as potential product sales. Its pipeline spans both ex vivo cell therapies and in vivo treatments targeting genetically defined diseases.
37GF Score
Get the complete analysis for LTS:0VRQ
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
